High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile

被引:63
作者
Baldewijns, M. M.
Thijssen, V. L.
Van den Eynden, G. G.
Van Laere, S. J.
Bluekens, A. M.
Roskams, T.
van Poppel, H.
De Bruine, A. P.
Griffioen, A. W.
Vermeulen, P. B.
机构
[1] Maasricht Univ, Dept Pathol, Angiogenesis Lab, Res Inst Growth & Dev, NL-6229 HX Maastricht, Netherlands
[2] Univ Hosp Maastricht, NL-6229 HX Maastricht, Netherlands
[3] Gen Hosp St Augustinus, Ctr Oncol, B-2650 Antwerp, Belgium
[4] Univ Antwerp Hosp, Lab Pathol Univ Antwerp, Translat Canc Res Grp, Edegem, Belgium
[5] Katholieke Univ Leuven Hosp, Dept Pathol, B-3000 Louvain, Belgium
[6] Katholieke Univ Leuven Hosp, Dept Urol, B-3000 Louvain, Belgium
关键词
angiogenesis; hypoxia; renal cell carcinoma;
D O I
10.1038/sj.bjc.6603796
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clear cell renal cell carcinoma (CC-RCC) is a highly vascularised tumour and is therefore an attractive disease to study angiogenesis and to test novel angiogenesis inhibitors in early clinical development. Endothelial cell proliferation plays a pivotal role in the process of angiogenesis. The aim of this study was to compare angiogenesis parameters in low nuclear grade (n = 87) vs high nuclear grade CC-RCC (n = 63). A panel of antibodies was used for immunohistochemistry: CD34/Ki-67, carbonic anhydrase IX, hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF). Vessel density (MVD-microvessel density), endothelial cell proliferation fraction (ECP%) and tumour cell proliferation fraction (TCP%) were assessed. mRNA expression levels of angiogenesis stimulators and inhibitors were determined by quantitative RT-PCR. High-grade CC-RCC showed a higher ECP% (P = 0.049), a higher TCP% (P = 0.009), a higher VEGF protein expression (P < 0.001), a lower MVD (Po 0.001) and a lower HIF-1a protein expression (P = 0.002) than low-grade CC-RCC. Growth factor mRNA expression analyses revealed a higher expression of angiopoietin 2 in low-grade CC-RCC. Microvessel density and ECP% were inversely correlated (Rho =-0.26, P = 0.001). Because of the imperfect association of nuclear grade and ECP% or MVD, CC-RCC was also grouped based on low/high MVD and ECP%. This analysis revealed a higher expression of vessel maturation and stabilisation factors (placental growth factor, PDGFB1, angiopoietin 1) in CC-RCC with high MVD, a group of CC-RCC highly enriched in low nuclear grade CC-RCC, with low ECP%. Our results suggest heterogeneity in angiogenic activity and vessel maturation of CC-RCC, to a large extent linked to nuclear grade, and, with probable therapeutic implications.
引用
收藏
页码:1888 / 1895
页数:8
相关论文
共 42 条
  • [1] Adini A, 2002, CANCER RES, V62, P2749
  • [2] BEDI A, 1995, CANCER RES, V55, P1811
  • [3] Tumorigenesis and the angiogenic switch
    Bergers, G
    Benjamin, LE
    [J]. NATURE REVIEWS CANCER, 2003, 3 (06) : 401 - 410
  • [4] Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
    Carmeliet, P
    Dor, Y
    Herbert, JM
    Fukumura, D
    Brusselmans, K
    Dewerchin, M
    Neeman, M
    Bono, F
    Abramovitch, R
    Maxwell, P
    Koch, CJ
    Ratcliffe, P
    Moons, L
    Jain, RK
    Collen, D
    Keshet, E
    [J]. NATURE, 1998, 394 (6692) : 485 - 490
  • [5] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [6] The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers
    Chakrabarti, J
    Turley, H
    Campo, L
    Han, C
    Harris, AL
    Gatter, KC
    Fox, SB
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (05) : 954 - 958
  • [7] Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma
    Chia, SK
    Wykoff, CC
    Watson, PH
    Han, C
    Leek, RD
    Pastorek, J
    Gatter, KC
    Ratcliffe, P
    Harris, AL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3660 - 3668
  • [8] Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO
  • [9] 2-#
  • [10] Distler JHW, 2003, Q J NUCL MED, V47, P149